Joinn Laboratories(China)Co.Ltd バランスシートの健全性

財務の健全性基準チェック /66

Joinn Laboratories(China)Co.Ltdの総株主資本はCN¥8.0B 、総負債はCN¥0.0で、負債比率は0%となります。総資産と総負債はそれぞれCN¥9.5BとCN¥1.5Bです。 Joinn Laboratories(China)Co.Ltdの EBIT はCN¥213.3Mで、利息カバレッジ比率-1.4です。現金および短期投資はCN¥3.2Bです。

主要情報

負債資本比率

CN¥0

負債

インタレスト・カバレッジ・レシオ	-1.4x
現金	CN¥3.22b
エクイティ	CN¥7.99b
負債合計	CN¥1.53b
総資産	CN¥9.53b

財務の健全性に関する最新情報

Recent updates

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Oct 01

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Jul 28

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Apr 04

財務状況分析

短期負債: 603127の短期資産 ( CN¥5.3B ) が短期負債 ( CN¥1.3B ) を超えています。

長期負債: 603127の短期資産 ( CN¥5.3B ) が長期負債 ( CN¥235.6M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 603127は負債がありません。

負債の削減: 603127 5 年前には負債がありませんでした。

債務返済能力: 603127には負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: 603127には負債がないため、利息支払いの負担は問題になりません。

Joinn Laboratories(China)Co.Ltd バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Joinn Laboratories(China)Co.,Ltd. SHS (China) to Be Deleted from OTC Equity

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Joinn Laboratories(China)Co.,Ltd. Announces Resignation of Yao Dalin as Executive Director and Vice General Manager

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Joinn Laboratories(China)Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Consensus EPS estimates fall by 27%

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Dividend of CN¥0.16 announced

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Consensus revenue estimates fall by 19%

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates fall by 19%

Price target decreased by 8.6% to CN¥22.33

Investor sentiment improves as stock rises 19%

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Now 23% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Price target decreased by 7.2% to CN¥25.92

Price target decreased by 7.3% to CN¥28.66

Now 20% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Consensus EPS estimates fall by 27%

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 700%

New minor risk - Share price stability

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 10%

Price target decreased by 11% to CN¥33.30

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to CN¥37.55

Now 25% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased by 8.7% to CN¥57.93

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥8.9m worth of stock

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 09, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.4% to CN¥70.19

Price target increased by 7.4% to CN¥76.57

Insider recently sold CN¥56m worth of stock

JOINN Laboratories (China) Co., Ltd. Provides Revenue Guidance for the Period January 1, 2022 to December 31, 2022

Insider recently sold CN¥57m worth of stock

Co-Founder & Vice Chairman recently sold CN¥31m worth of stock

Insider recently sold CN¥30m worth of stock

Co-Founder & Vice Chairman recently sold CN¥65m worth of stock

Price target decreased to CN¥71.30

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Co-Founder & Vice Chairman recently sold CN¥180m worth of stock

Price target increased to CN¥86.02

Insider recently sold CN¥60m worth of stock

Now 21% undervalued after recent price drop

Price target decreased to CN¥74.80

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.11 in 2Q 2021)

Joinn Laboratories(China)Co.,Ltd. SHS (China) to Be Deleted from OTC Equity

Joinn Laboratories(China)Co.,Ltd. to Report Q2, 2022 Results on Aug 30, 2022

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Period from 1 January 2022 to 30 June 2022

Senior Vice GM recently sold CN¥233k worth of stock

財務の健全性基準チェック /66